The latest research news in genetics and genomics.
The new company, FonesLife, will use Somalogic's SomaScan technology for health monitoring and assessing patient illness risk.
The funding will be used to continue work on a blood-based test for the detection of concussions at the point of care, point of injury, or at a remote testing site.
Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.
The firm initially plans to apply the method, which measures the size of specific macrophages in blood, to predict lung cancer immunotherapy response.
An analysis of 3,000 subjects found the test could identify diabetes patients at risk of developing chronic kidney disease within the next four years.
